• Considering whether Elanco Animal Health at around US$19.80 is still offering value, or if the easy gains are already behind it.
• The stock is down 7.6% over the past week, 16.4% over the past month and 12.1% year to date, even though it is up 51.4% over the last year and 129.7% over three years, while the five year return sits at a decline of 44.2%.
• These mixed returns arrive as investors continue to reassess the outlook for animal health companies and their ability to sustain growth in demand for veterinary and livestock products. Broader sector sentiment and expectations around interest rates and funding conditions have also been influencing how much risk investors are willing to take in healthcare related stocks.
• In that context, Elanco Animal Health currently scores a valuation check of 6 out of 6. The next sections will break down what different valuation approaches are signaling today, and then outline a way to bring those methods together into a clearer picture of value.

Approach 1: Elanco Animal Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting future cash flows and then discounting them back to today, using a required rate of return. It focuses on the cash the business may generate for shareholders rather than just earnings multiples.

For Elanco Animal Health, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow is about $355.3 million. Analyst estimates and extrapolated figures point to projected free cash flow of $742.0 million by 2030, with a detailed path that includes forecast cash flows between 2026 and 2035 that are discounted back to today within the model.

Pulling these discounted projections together results in an estimated intrinsic value of about $36.61 per share, compared with a current share price around $19.80. On this basis, the model indicates the stock trades at about a 45.9% discount to its estimated value, which is a sizable gap for investors to consider.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Elanco Animal Health is undervalued by 45.9%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks.

Approach 2: Elanco Animal Health Price vs Sales

For companies where earnings are not the main reference point, the P/S ratio can be a useful way to think about value because it compares what the market is paying for each dollar of revenue. Investors usually accept a higher or lower P/S based on expectations for future growth and the level of risk they see in those revenues.

Elanco Animal Health currently trades on a P/S of 2.02x. This sits below the Pharmaceuticals industry average P/S of 5.72x and below the peer group average of 2.35x. On the surface, that suggests the stock is priced more conservatively than many sector peers.

Simply Wall St’s Fair Ratio for Elanco on a P/S basis is 4.09x. This proprietary measure estimates what the P/S could be given factors such as earnings growth, profit margins, Elanco’s industry, market cap and key risks. Because it adjusts for these company specific attributes, it can be more informative than a simple comparison with broad industry or peer averages.

Comparing the Fair Ratio of 4.09x with the current P/S of 2.02x points to the stock trading below this model based reference point.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Elanco Animal Health Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives let you attach a clear story about Elanco Animal Health to the numbers by linking your view on its future revenue, earnings and margins to a forecast, and then to a Fair Value that you can compare directly with the current share price. All of this happens inside the Simply Wall St Community page, where these Narratives update automatically when fresh news or earnings land. For example, one investor might lean toward a cautious Elanco view with a Fair Value around US$22.49 that reflects slower growth and tighter margins. Another might back a more optimistic Elanco story with a Fair Value closer to US$32.00 that assumes faster growth and stronger profitability. Narratives put both of those perspectives side by side so you can decide which story you believe fits the stock today.

Do you think there's more to the story for Elanco Animal Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.